A Study to Investigate the Efficacy of an Experimental Dentifrice Containing Stannous Fluoride in Improving Gingival Health
An 8-Week Randomized, Controlled, Examiner-Blind, Clinical Study Investigating the Efficacy of an Experimental Dentifrice Containing Stannous Fluoride in Improving Gingival Health
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Haleon Response Center
- Telefonnummer: +441932959500
- E-Mail: ww.clinical-trial-register@haleon.com
Studienorte
-
-
Indiana
-
Fort Wayne, Indiana, Vereinigte Staaten, 46825
- Rekrutierung
- Salus Research Inc
-
Kontakt:
- Jeffery L Milleman, DDS
- E-Mail: Milleman@Salusresearch.us
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Participant provision of a signed and dated informed consent document indicating that the participant will have been informed of all pertinent aspects of the study before any assessment is performed.
- A participant who is willing and able to comply with scheduled visits, treatment plan and other study procedures, study restrictions, Lifestyle considerations.
- A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the participant's ability to understand and follow study procedures and requirements.
Exclusion Criteria:
- A participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
- A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
- A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical, psychiatric condition or laboratory abnormality or any other clinical serious or unstable conditions (Example(e.g.), cardiovascular diseases, diabetes, liver disorders, and kidney disorders) that may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
- A participant who is a pregnant female (self-reported) or intending to become pregnant over the duration of the study.
- A female participant who is breastfeeding.
- A participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
- A participant unwilling or unable to comply with the lifestyle considerations described in this protocol.
- A participant who is a current smoker or an ex-smoker (including vaping) who stopped within 6 months of Screening.
- A participant who is using smokeless forms of tobacco (example, chewing tobacco, gutkha, paan containing tobacco, nicotine-based e-cigarettes).
- A participant who has diagnosed xerostomia or is taking any medication that in the view of the investigator, is causing xerostomia.
- A participant who has a medical condition which could directly influenced gingival bleeding (e.g., type 2 diabetes).
- A participant who has a bleeding disorder that could affected study outcomes and/or participant safety.
- A participant who has a recent history (within the last year) of alcohol or other substance abuse.
- A participant who has a severe oral condition (e.g., acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study.
- Presence of a tongue or lip piercing, or any other oral feature that could interfere with the usage of a toothbrush.
- A participant currently taking any such medication or oral care product which in opinion of the investigator could affect gingival condition.
Dental exclusions:
- A participant who has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
- A participant who has dentures (partial or full).
- A participant who has fixed orthodontic appliances or is undergoing active or recent (within 3 months of Screening) orthodontic treatment, which, in the opinion of the investigator, could interfere with study procedures, assessments or outcomes.
- A participant who has other orthodontic devices (e.g., bands, fixed retainers, or removable retainers) that could, in the opinion of the investigator, interferes with study procedures, assessment, or outcomes.
- A participant who has numerous restorations in a poor state of repair.
- A participant who has any dental condition (e.g., overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
- A participant who has had dental prophylaxis and teeth bleaching within 12 weeks of Screening.
- A participant who has high levels of extrinsic stain or calculus deposits, in the opinion of the investigator, that could interfered with plaque assessments.
- A participant who has previously been enrolled in this study.
- A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Test Dentifrice
Participants will brush their teeth thoroughly for at least one timed minute twice daily (morning and evening) for 8 Weeks, using a full ribbon of Test Dentifrice on the head of the toothbrush provided.
|
Experimentelle Zahnpasta mit 0,454 % w/w SnF2.
|
|
Aktiver Komparator: Reference Dentifrice
Participants will brush their teeth thoroughly for at least one timed minute twice daily (morning and evening) for 8 Weeks, using a full ribbon of Reference Dentifrice on the head of the toothbrush provided.
|
A marketed regular fluoride dentifrice.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from Baseline in Overall Modified Gingival Index (MGI) at Week 8
Zeitfenster: Baseline and Week 8
|
The MGI assessment is a non-invasive visual evaluation to assess the symptoms of gingivitis.
It will be assessed on all scorable teeth.
For each tooth, 3 scores will be recorded and will be scored on a 5-point scale ranging from 0 to 4, where 0 equals (=) Absence of inflammation, 1= Mild inflammation; slight or little change in color; little change in texture of any portion of the marginal/ papillary gingival unit, 2= Mild inflammation; criteria as above, but involving the entire marginal/ papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal/ papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal/ papillary gingival unit, spontaneous bleeding, congestion, or ulceration.
Change from Baseline= Week 8 score minus Baseline score.
Lower scores indicate symptom improvement.
|
Baseline and Week 8
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from Baseline in Interproximal MGI at Week 8
Zeitfenster: Baseline and Week 8
|
The MGI assessment is a non-invasive visual evaluation to assess the symptoms of gingivitis.
It will be assessed on all scorable teeth.
For each tooth, 3 scores will be recorded and will be scored on a 5-point scale ranging from 0 to 4, where 0= Absence of inflammation, 1= Mild inflammation; slight or little change in color; little change in texture of any portion of the marginal/ papillary gingival unit, 2= Mild inflammation; criteria as above, but involving the entire marginal/ papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal/ papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal/ papillary gingival unit, spontaneous bleeding, congestion, or ulceration.
Change from Baseline= Week 8 score minus Baseline score.
Lower scores will indicate symptom improvement.
|
Baseline and Week 8
|
|
Change from Baseline in Overall Turesky Modification of the Quigley Hein Plaque Index (TPI) at Week 8
Zeitfenster: Baseline and Week 8
|
TPI will be used to assess plaque on all gradable teeth.
The plaque will first be disclosed using a plaque disclosing dye solution.
The TPI will be assessed on the facial and lingual surfaces of each scorable tooth.
Three scores will be recorded buccally/labially and three scores lingually/palatally.
The disclosed plaques will be scored using a 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 millimeter[mm]) at the cervical margin, 3= Band of plaque wider than 1 mm but covering less than (<) 1/3 of the tooth surface, 4= Plaque covering greater than or equal to (≥) 1/3 but < 2/3 of the tooth surface, 5= Plaque covering ≥ 2/3 of the tooth surface.
Change from Baseline= Week 8 score minus Baseline score.
Lower scores will indicate symptom improvement.
|
Baseline and Week 8
|
|
Change from Baseline in Interproximal TPI at Week 8
Zeitfenster: Baseline and Week 8
|
TPI will be used to assess plaque on all gradable teeth.
The plaque will first be disclosed using a plaque disclosing dye solution.
The TPI will be assessed on the facial and lingual surfaces of each scorable tooth.
Three scores will be recorded buccally/labially and three scores lingually/palatally.
The disclosed plaques will be scored using a 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering < 1/3 of the tooth surface, 4= Plaque covering ≥ 1/3 but < 2/3 of the tooth surface, 5= Plaque covering ≥ 2/3 of the tooth surface.
Change from Baseline= Week 8 score minus Baseline score.
Lower scores will indicate symptom improvement.
|
Baseline and Week 8
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Jeffery L Milleman, DDS, Salus Research Inc
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 400347
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .